Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration

  • J Med Chem. 2008 Apr 10;51(7):2147-57. doi: 10.1021/jm701437d.
John J Caldwell  1 ,  Thomas G Davies ,  Alastair Donald ,  Tatiana McHardy ,  Martin G Rowlands ,  G Wynne Aherne ,  Lisa K Hunter ,  Kevin Taylor ,  Ruth Ruddle ,  Florence I Raynaud ,  Marcel Verdonk ,  Paul Workman ,  Michelle D Garrett ,  Ian Collins
Affiliations
  • 1. Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, U.K.
Abstract

Fragment-based screening identified 7-azaindole as a protein kinase B inhibitor scaffold. Fragment elaboration using iterative crystallography of inhibitor-PKA-PKB chimera complexes efficiently guided improvements in the potency and selectivity of the compounds, resulting in the identification of nanomolar 6-(piperidin-1-yl)purine, 4-(piperidin-1-yl)-7-azaindole, and 4-(piperidin-1-yl)pyrrolo[2,3- d]pyrimidine inhibitors of PKBbeta with antiproliferative activity and showing pathway inhibition in cells. A divergence in the binding mode was seen between 4-aminomethylpiperidine and 4-aminopiperidine containing molecules. Selectivity for PKB vs PKA was observed with 4-aminopiperidine derivatives, and the most PKB-selective inhibitor (30-fold) showed significantly different bound conformations between PKA and PKA-PKB chimera.